The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes
    • eBooks

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Pathology Captures
Subscribe
Subscribe

False

The Pathologist / Issues / 2026 / October / Gold-Based Sensor Finds Bugs, Fast
Microbiology & Immunology Infectious Disease Point of care testing Screening and monitoring Technology and innovation

Gold-Based Sensor Finds Bugs, Fast

New filtration technique detects low concentrations of bacteria and assesses antibiotic susceptibility, offering a potential faster route to diagnosing sepsis and other serious infections

10/30/2026 News 2 min read
  • Full Article
  • Summary
  • Takeaways
  • Listen
  • Scorecard
  • Quiz
  • Poll

Share

Clinical Scorecard: Gold-Based Sensor Finds Bugs, Fast

At a Glance

CategoryDetail
ConditionClinical topic addressed by the source article: Gold-Based Sensor Finds Bugs, Fast
Key MechanismsMechanisms or clinical associations described in the source article.
Target PopulationPatients or participants described in the source article.
Care SettingPotential future use in clinical microbiology laboratories; clinical performance has not been established, and validation with patient blood samples is needed.

Key Highlights

  • In E. coli model experiments, bacterial capture efficiency exceeded 99.9% at the concentrations studied.
  • In E. coli model experiments, the platform detected 1,000 CFU/mL; adding a 1-hour culture step improved sensitivity to 10 CFU/mL.
  • Molecular fingerprints distinguished E. coli, Staphylococcus aureus, and Klebsiella pneumoniae.
  • In E. coli experiments, signals after amikacin or ampicillin exposure were distinguishable within 2 hours.
  • The article calls for further validation using patient blood samples and a broader range of pathogens.

Guideline-Based Recommendations

Diagnosis

  • Study finding: the platform detected and distinguished bacterial species in reported experiments; clinical diagnostic performance in patient samples remains to be validated.

Management

  • The article describes potential use of rapid susceptibility information to support antimicrobial decisions; it does not provide treatment recommendations.

Monitoring & Follow-up

  • Study finding: changes in bacterial signals after antibiotic exposure were distinguishable within 2 hours in reported E. coli experiments.

Risks

  • The article identifies validation with patient blood samples and a broader range of pathogens as necessary before clinical use can be established.

Patient & Prescribing Data

No patient cohort or patient-level prescribing data were reported. The study reports E. coli experiments and molecular identification of E. coli, S. aureus, and K. pneumoniae.

In E. coli experiments, signals declined after amikacin exposure, indicating susceptibility, while signals continued to increase after ampicillin exposure, indicating reduced susceptibility.

Clinical Best Practices

  • Interpret the reported detection and susceptibility findings as experimental results, not established clinical performance.
  • Further validation with patient blood samples and a broader range of pathogens is needed, as stated in the article.

Related Resources & Content

  • Study published in Small Methods; article reports no source URL.

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Newsletters

Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Your Privacy Choices
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.